Domestic companies’ strategy to avoid ‘Pradaxa’ patent

Domestic pharmaceutical companies are altering strategies on patent suits to develop generics of ‘Pradaxa(generic name: dabigatran).’

As keeping losing on its substance and composition patent nullification trials, they are changing their way to avoid them instead of nullifying them.

Recently, Samjin Pharm, Boryung Pharm, Dasan Medichem, Chong Kun Dang and Jeil Pharmaceutical applied for the c...